Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NovaGo Therapeutics

Request full access

Human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration

Schlieren, SwitzerlandFounded 2015Biotech & Life Sciences

About NovaGo Therapeutics

NovaGo Therapeutics is a Schlieren, Switzerland clinical-stage biotech developing anti-Nogo-A biologics to promote nerve regeneration and functional recovery after central-nervous-system injury and disease, including acute spinal cord injury, stroke and secondary progressive multiple sclerosis. Founded on research identifying Nogo-A as a key inhibitor of neuronal regeneration, its lead candidate NG004 is a fully human therapeutic antibody designed to enable nerve-fiber outgrowth and neuroplasticity where approved regenerative options are lacking. In August/September 2026 NovaGo closed a CHF 24 million (USD 30 million) Series B co-led by Neurimmune and Pureos, with existing and new investors, complemented by non-dilutive support from the Swiss Paraplegic Foundation and Wings for Life, to run a 120-patient randomised double-blind proof-of-concept trial in acute spinal cord injury across Germany, Spain and Switzerland after encouraging Phase 1 results. Sources: PR Newswire / NovaGo 2 Sep 2026; Neurimmune; Wyss Zurich.

Source: Dealroom company data

At a glance

Status
Operational
Employees
10
Open positions
None listed
Dealroom signal
74.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Sep 2026 $30M $120M Wings for Life · Neurimmune Holding · Swiss InsurEvolution Partners Holding · Pureos Bioventures ↗
SERIES A✓Equity / VC Mar 2019 $9.7M $39M Neurimmune Holding · Pureos Bioventures ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

NovaGo Therapeutics website traffic

Latest recorded traffic for NovaGo Therapeutics is 720 monthly website visits, down 26.5% over the last three months. NovaGo Therapeutics's team grew 0% over the past year.

Latest monthly visits720 3-month web change-26.5% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NovaGo Therapeutics in the Schlieren ecosystem

Live from Dealroom

The NovaGo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Neurimmune Holding
  • Pureos Bioventures
  • Wings for Life
  • Swiss InsurEvolution Partners Holding

Other known investors2 additional known investors

  • University of Zürich
  • Patrick Aisher
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See NovaGo Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.